Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
DXS International PLC - Leicestershire, England-based healthcare information and clinical decision support systems - Posts revenue of GB1.7 million for the six months that ended on October 31, up 6.3% from £1.6 million a year earlier. However, swings to a pretax loss of £131,269 from a profit of £21,427 due to ‘increased operating costs and depreciation’, it explains. Cost of sales increases to £229,308 from £181,952 a year before. Depreciation & amortisation rises to £354,363 from £274,093.
Chief Executive Officer David Immelman says: ‘With the persistent challenges facing the [UK National Health Service], our solutions have never been more aligned to NHS priorities. Our new products are currently being trialled in numerous clinical commissioning groups with significant results demonstrated in reducing referral rejections and drastically cutting waiting times. We are solely focused in converting these trials to commercial contracts.’
Current stock price: last traded on Nov 30 at 4.5 pence each
12-month change: down from 14p on Jan 20 last year
By Xindi Wei, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.